Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

MDUFA IV Takes Shape: A Catalogue Of Draft Commitments

Executive Summary

More specific details have emerged about the agreement "in principle" announced last week by FDA and industry negotiators on the next round of the medical device user-fee program, which will extend from fiscal years 2018 through 2022.


Related Content

Obamacare Repeal May Be Delaying User-Fee Bills, Rep. DeGette Says
Gulfo Might Reevaluate Negotiated User Fees If Selected US FDA Commish
A Burning FDA Hiring Freeze Question: What About User-Fee-Supported Staff?
MDR Reporting: FDA Embraces Adverse Event Summaries Under MDUFA IV, But Flouts Similar FDAAA Mandate
Must-Do Guidance Development: What's On Tap From Cures, MDUFA IV
Congress To Focus On Cures And MACRA Oversight, MDUFA In 2017
FDA Puts Lab-Developed Test Oversight Plans On Hold
MDUFA IV Fees Unveiled: Changes For 510(k)s, Small Business, De Novos
Public Invited To Vet Draft User-Fee Agreement At Nov. 2 Meeting
Industry, US FDA Strike $1Bn Deal After Contentious User-Fee Negotiations